ORAMED PHARMACEUTICALS INC.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

ORMP$4.00+3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Equity

in thousands

Attributable to Company’s Stockholders

Additional · Total · Non-
Common Stock · paid-in · Accumulated · stockholders’ · controlling · Total
	Shares	$	capital	deficit	equity	interests	Equity
In thousands
BALANCE AS OF JANUARY 1, 2024	40,339	485	320,892	(157,556)	163,821	(928)	162,893
STOCK-BASED COMPENSATION	618	7	3,991	-	3,998	-	3,998
STOCK-BASED COMPENSATION OF SUBSIDIARY	-		-	-	-	53	53
REPURCHASE AND RETIREMENT OF COMMON STOCK	(1,037)	(12)	(2,482)		(2,494)		(2,494)
NET LOSS				(19,060)	(19,060)	(43)	(19,103)
BALANCE AS OF DECEMBER 31, 2024	39,920	480	322,401	(176,616)	146,265	(918)	145,347

Attributable to Company’s Stockholders

Additional · Total · Non-
Common Stock · paid-in · Accumulated · stockholders’ · controlling · Total
	Shares	$	capital	deficit	equity	interests	Equity
In thousands
BALANCE AS OF JANUARY 1, 2023	39,564	476	314,417	(163,081)	151,812	(656)	151,156
SHARES ISSUED FOR SERVICES	3	*	9	-	9	-	9
ISSUANCE OF COMMON STOCK, NET	193	2	2,426	-	2,428	-	2,428
STOCK-BASED COMPENSATION	579	7	4,040	-	4,047	-	4,047
STOCK-BASED COMPENSATION OF SUBSIDIARY	-	-	-	-	-	165	165
NET INCOME (LOSS)	-	-	-	5,525	5,525	(437)	5,088
BALANCE AS OF DECEMBER 31, 2023	40,339	485	320,892	(157,556)	163,821	(928)	162,893

*	Represents an amount of less than $1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.